Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug;87(2):272-80.
doi: 10.4269/ajtmh.2012.11-0718.

Evidence for stopping mass drug administration for lymphatic filariasis in some, but not all local government areas of Plateau and Nasarawa States, Nigeria

Jonathan D King  1 , Abel Eigege, John Umaru, Nimzing Jip, Emmanuel Miri, Jonathan Jiya, Kal M Alphonsus, Yohanna Sambo, Patricia Graves, Frank Richards Jr
Affiliations

Evidence for stopping mass drug administration for lymphatic filariasis in some, but not all local government areas of Plateau and Nasarawa States, Nigeria

Jonathan D King et al. Am J Trop Med Hyg. 2012 Aug.

Abstract

An average of six annual rounds of ivermectin and albendazole were distributed in Plateau and Nasarawa States, Nigeria, to eliminate lymphatic filariasis. From 2007 to 2008, population-based surveys were implemented in all 30 local government areas (LGAs) of the two states to determine the prevalence of Wuchereria bancrofti antigenemia to assess which LGA mass drug administration (MDA) could be halted. In total, 36,681 persons from 7,819 households were examined for filarial antigen as determined by immunochromatographic card tests. Overall antigen prevalence was 3.05% (exact upper 95% confidence interval [CI] = 3.41%) with an upper 95% CI range by LGA of 0.50-19.3%. Among 3,233 children 6-7 years of age, overall antigen prevalence was 1.71% (exact upper 95% CI = 2.19%), too high to recommend generally halting MDA in the two-state area. However, based on criteria of < 2% antigenemia among persons > 2 years of age, stopping MDA was recommended for 10 LGAs.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Prevalence of Wuchereria bancrofti antigenemia in persons > 2 years of age in Plateau and Nasarawa States, Nigeria 2008.
Figure 2.
Figure 2.
Age and gender-specific prevalence of Wuchereria bancrofti antigenemia in Plateau and Nasarawa States, Nigeria 2008 (N = 36,681).
Figure 3.
Figure 3.
Antigen prevalence among adults > 14 years of age living in baseline mapping villages in 2000 and 2008.
See this image and copyright information in PMC

References

    1. World Health Assembly Resolution 50.29 Elimination of Lymphatic Filariasis as a Public Health Problem. 1997. http://www.who.int/lymphatic_filariasis/resources/WHA_50%2029.pdf Available at. Accessed October 15, 2009.
    1. World Health Organization Global programme to eliminate lymphatic filariasis: progress report on mass drug administration in 2010. Wkly Epidemiol Rec. 2011;86:377–388. - PubMed
    1. World Health Organization Meeting of the International Task Force for Disease Eradication, April 2011. Wkly Epidemiol Rec. 2011;86:341–352. - PubMed
    1. Njepuome NA, Hopkins DR, Richards FO, Jr, Anagbogu IN, Pearce PO, Jibril MM, Okoronkwo C, Sofola OT, Withers PC, Jr, Ruiz-Tiben E, Miri ES, Eigege A, Emukah EC, Nwobi BC, Jiya JY. Nigeria's war on terror: fighting dracunculiasis, onchocerciasis, lymphatic filariasis, and schistosomiasis at the grassroots. Am J Trop Med Hyg. 2009;80:691–698. - PubMed
    1. Hopkins DR, Eigege A, Miri ES, Gontor I, Ogah G, Umaru J, Gwomkudu CC, Mathai W, Jinadu M, Amadiegwu S, Oyenekan OK, Korve K, Richards FO. Lymphatic filariasis elimination and schistosomiasis control in combination with onchocerciasis control in Nigeria. Am J Trop Med Hyg. 2002;67:266–272. - PubMed

Publication types

MeSH terms

LinkOut - more resources